Genistein is a small molecule found in vegetables, e.g. soy. It is classified as a phytoestrogen (7) as it binds to and regulates the activity of the estrogen receptor beta (ERβ) (8). This receptor is considered to have multiple beneficial effects in diseases such as neurodegenerative diseases, including Parkinson’s disease and multiple sclerosis (MS), solid tumors, including pancreatic cancer as well as several diseases related to women’s health such as hot flushes, osteoporosis and vaginal atrophy.

However, due to genistein’s poor pharmaceutical properties it has never been developed as a therapeutic. With Axcentua’s technology to screen for and develop new crystalline solid forms of genistein with improved pharmaceutical properties such as genistein sodium salt dehydrogenade (genistein-SSDH), or AXP107-11, it is now possible for the first time to evaluate the potential therapeutic advantages of genistein in a number of therapeutic areas. Genistein-SSDH has already been granted a US patent and patent applications of close to ten other solid crystalline forms of genistein have already been filed.